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Primary hyperoxaluria is characterized by severe urolithiasis,
nephrocalcinosis, and early renal failure. As treatment
options are scarce, we aimed for a new therapeutic tool using
colonic degradation of endogenous oxalate by Oxalobactor
formigenes. Oxalobacter was orally administered for 4 weeks
as frozen paste (IxOC-2) or as enteric-coated capsules
(IxOC-3). Nine patients (five with normal renal function, one
after liver–kidney transplantation, and three with renal
failure) completed the IxOC-2 study. Seven patients (six with
normal renal function and one after liver–kidney
transplantation) completed the IxOC-3 study. Urinary oxalate
or plasma oxalate in renal failure was determined at baseline,
weekly during treatment and for a 2-week follow-up. The
patients who showed 420% reduction both at the end of
weeks 3 and 4 were considered as responders. Under IxOC-2,
three out of five patients with normal renal function showed
a 22–48% reduction of urinary oxalate. In addition, two renal
failure patients experienced a significant reduction in plasma
oxalate and amelioration of clinical symptoms. Under IxOC-3
treatment, four out of six patients with normal renal function
responded with a reduction of urinary oxalate ranging
from 38.5 to 92%. Although all subjects under IxOC-2
and 4 patients under IxOC-3 showed detectable levels of
O. formigenes in stool during treatment, fecal recovery
dropped directly at follow up, indicating only transient
gastrointestinal-tract colonization. The preliminary data
indicate that O. formigenes is safe, leads to a significant
reduction of either urinary or plasma oxalate, and is a
potential new treatment option for primary hyperoxaluria.
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Primary hyperoxaluria type 1 (PH 1) is a rare, autosomal
recessive inherited disease caused by low or absent activity of
the liver-specific peroxisomal alanine:glyoxylate aminotrans-
ferase.1–3 Elevated urinary oxalate excretion (UOx41 mmol/
1.73 m2 body surface area (BSA)/day, normal o0.51,3) and
urinary super saturation with respect to calcium-oxalate
(bUCaOx410 rel. units, normal male o6.3, normal female
o5.54) are the hallmarks of the disease-causing renal calculi,
medullary nephrocalcinosis, or both.1 With disease progres-
sion and declining renal function, systemic calcium-oxalate
(CaOx) crystal deposition occurs.
Current therapeutic options are scarce and are only
completely successful in a minority of patients.5–7 Hence,
we aimed for a new therapeutic tool and speculated
that colonic degradation of oxalate by Oxalobacter formigenes
(O. formigenes) may provide a suitable transepithelial
gradient for the enteric elimination of endogenously
produced oxalate.
O. formigenes is an obligate anaerobic bacterium naturally
colonizing the colon of vertebrates, including humans,
which utilizes oxalic acid as its sole source of energy.8
Oxalate degradation by O. formigenes involves three unique
proteins, an oxalate:formate membrane transporter, oxalyl-
CoA decarboxylase, and formyl-CoA transferase. The genes
for all three proteins have been cloned and sequenced.9–11
Robust colonization with O. formigenes is in the range
of 107–108 colony forming units (CFUs) per gram wet fecal
sample, translating to a degrading capacity of up to 1 g
(11.1 mmol) of oxalate/day in the human gut.
Children acquire O. formigenes during early childhood
and fecal samples from 70 to 80% of the adult population test
positive for this bacterium.12–16 A much lower O. formigenes
colonization rate was found in recurrent CaOx kidney stone-
formers and in subjects with enteric hyperoxaluria.13,14,17–20
The importance of O. formigenes in degrading dietary
oxalate has been shown in animal models where significant
decreases in UOx occurred following either colonization with
O. formigenes13 or its daily administration.21
Besides absorption, oxalate secretory pathways for
extra-renal oxalate elimination have also been recently
identified in the large intestine.22 It has been hypothesized
that intestinal degradation of oxalate by O. formigenes can
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contribute to maintenance of a transepithelial gradient
favoring a passive paracellular movement of oxalate
from blood to the intestinal lumen.22 Recent work by Hatch
with rat colonic mucosa to modulate the handling of
oxalate in colonized animals leading to the induction
of enteric secretion/excretion. The ability of O. formigenes
to stimulate secretion of endogenously produced oxalate
and to degrade it in the intestine (use as a carbon source)
supports the hypothesis that this microorganism can be
of benefit for PH patients by lowering their urinary
oxalate excretion.
RESULTS
The individual urinary oxalate/creatinine ratios in both
studies are shown in Figures 1 and 2 and mean urinary
oxalate excretion 7s.d. is given in Tables 1 and 2. In
addition, mean values of other lithogenic (calcium) and
stone-inhibitory (citrate, magnesium) substances, as well as
bUCaOx (7s.d., range) are presented in Tables 1 and 2. All the
subjects showed a good compliance with the 24 h urine
collection as was evident from total volumes and urinary
creatinine levels (Tables 1 and 2).
In the IxOC-2 (Oxalobacter was orally administered for 4
weeks as frozen paste) study, UOx was monitored in five
patients with normal renal function (Figure 1). Three were
found to be responders and their urinary oxalate/creatinine
ratios showed a 22–48% reduction as compared to the
baseline. Mean UOx levels (expressed as mmol/1.73 m
2/24 h)
for all the patients, although lower at weeks 3 and 4, did not
decrease significantly during treatment with IxOC-2 (Table 1,
P¼NS). A significant increase in mean urinary calcium
excretion was observed at weeks 4 and 5 (Po0.02).
Concomitantly, urinary bCaOx increased significantly at week
4 of treatment (Po0.05).
In patient no. 10 after successful combined liver–kidney
transplantation (LKTx), urinary oxalate was also monitored,
but did not drop significantly during treatment. However, her
POx declined from 18 to 5.5 mmol/l at the end of week 3 (ref.
value is 6.371.1 mmol/l), but increased again after termina-
tion of treatment.
In the IxOC-3 (Oxalobacter was orally administered for 4
weeks as enteric-coated capsules) study, UOx was monitored
in six patients with normal renal function (Figure 2).
Four out of the six patients were found to be responders
and their urinary oxalate/creatinine ratios showed a
38.5–92% reduction as compared to the baseline values.
Patient no. 19, who was treated after successful combined
LKTx, again did not show a reduction in urinary oxalate
excretion. In this study, a statistical significant decrease
in the mean UOx excretion (mmol/1.73 m
2/24 h) was achieved
in all weeks as compared to baseline and the decline
was highly significant (Po0.001) at the end of treatment
weeks 3 and 4 (Table 2). Mean urinary oxalate increased
again within 1 week of stopping the treatment, but
another decrease was observed at the end of week 6.
However, long-term follow-up in the majority of the patients
(12 months) indicated that the urinary oxalate excretion
returned back to their historical higher levels. Urinary bCaOx
decreased significantly at weeks 3 and 4 of IxOC-3 treatment
(Table 2, Po0.05).
A decrease of plasma oxalate levels was observed in 10/13
patients with normal or stable kidney function leading to a
significant reduction of mean plasma oxalate in both studies
(Tables 1 and 2, Po0.05).
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Figure 1 | Urinary oxalate/creatinine ratio (mmol/mol) in patients with normal renal function (patient no. 1–4 and 9) and in one
patient after combined liver–kidney transplantation (no. 10) with stable kidney function under treatment with IxOC-2 at baseline,
treatment phase (weeks 1–4) and at short follow up (weeks 5 and 6).
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Treatment efficacy was followed by weekly measurement
of plasma oxalate in three end stage renal failure (ESRF)
patients enrolled in the IxOC-2 study. Plasma oxalate levels
decreased under treatment in patients no. 6 and no. 8,
reaching nearly normal levels in patient no. 8 at weeks 3–5
(Figure 3). Patient no. 6 was treated for 5 weeks. The plasma
oxalate levels remained low in both patients 1 week after
treatment was stopped but started to increase by the end of
2-week post-treatment follow-up. Consistent decrease in
plasma oxalate was not observed in Patient no. 11 in whom
some compliance issues were suspected. A lower POx level was
only seen in week 1 of treatment in this patient.
Patient no. 10 after combined liver–kidney transplantation
and the ESRF patient no. 6, both with systemic oxalosis,
reported an amelioration of clinical symptoms under
therapy, with less pain due to oxalate osteopathy (no. 6 and
10) or CaOx skin deposits (no. 10).
In the IxOC-2 study, fecal samples were tested for the
presence/absence of O. formigenes by the polymerase chain
reaction (PCR)-based method. Only patient no. 1 was
colonized at baseline and remained colonized throughout
the study and thereafter. In all other patients, fecal recovery
of orally fed O. formigenes was observed during the treatment
phase, which was lost during the 2 week follow-up except in
patient no. 6.
In the IxOC-3 study, two patients were colonized at
baseline, including patient no. 16, who already participated
in the IxOC-2 study. Fecal recovery of orally fed O. formigenes
was highly variable in this study, and at the end of the
4-week treatment only four out of seven patients showed
the bacterium in their stool specimens. Only patients
who were colonized at baseline remained colonized 2-weeks
post-treatment.
The intestinal oxalate absorption was p10% in all the
patients except for patient no. 19, whose baseline oxalate
absorption was 11%. All values were within or even
below 7.974% (mean7s.d. of the reference range24). In the
IxOC-2 study, a significant difference in the mean oxalate
absorption at baseline and post-treatment was observed
(Po0.02, Table 1). However, no difference was found in the
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Figure 2 | Urinary oxalate/creatinine ratio (mmol/mol) in patients with normal renal function (no. 12–18) and in one patient after
combined liver–kidney transplantation and stable kidney function (no. 19) under treatment with IxOC-3 at baseline, treatment phase
(weeks 1–4) and at short follow up (weeks 5 and 6). Week 2 urine of patient no. 15 got lost in mail.
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Table 1 | Mean values7s.d. (range) for urinary excretion parameters, urinary calcium-oxalate saturation, plasma oxalate, and intestinal oxalate absorption of the
patients with normal (No. 1–4 and No. 9) or stable (No. 10) renal function included in the IxOC-2 study
Baseline, Week 1 Week 2 Week 3 Week 4 Week 5 Week 6
Mean7s.d. (range) Mean7s.d. (range) Mean7s.d. (range) Mean7s.d. (range) Mean7s.d. (range) Mean7s.d. (range) Mean7s.d. (range)
Urinary oxalate (mmol/1.73m2/24 h) 1.6471.17 (0.64–3.82) 1.9671.68 (0.71–5.24) 1.9371.27 (0.88–4.38) 1.4270.86 (0.77–2.87) 1.5370.92 (0.81–3.18) 1.3970.42 (1.05–1.96) 1.3770.55 (0.81–2.32)
Calcium (mg/kg body weight/24 h) 1.570.73 (0.6–2.35) 1.6470.25 (1.37–2.04) 1.5170.52 (1.05–2.17) 1.6970.42 (1.14–2.13) 2.0770.77a (1.02–2.99) 2.2170.58b (1.55–2.95) 1.7470.87 (0.96–3.2)
Citrate (mmol/1.73m2/24 h) 3.772.11 (1.09–6.11) 3.4370.8 (2.37–4.56) 3.271.72 (1.16–5.67) 3.6471.34 (2.28–5.02) 3.5971.85 (1.17–5.5) 2.9770.82 (1.86–3.8) 3.4271.78 (2.4–6.99)
Magnesium (mmol/1.73m2/24 h) 4.5871.78 (2.13–7.66) 6.172.41 (3.66–10.23) 6.0671.53a (4.36–7.84) 5.971.4 (3.58–7.96) 6.7373.06 (3.29–11.69) 6.8871.58c (4.34–9.05) 5.6572.0 (3.38–8.04)
bUCaOx (rel. units) 4.4471.22 (2.94–6.46) 4.5771.21 (3.45–6.39 4.8870.72 (3.84–5.8) 4.5170.7 (3.3–5.4) 5.4971.6
c (3.07–7.71) 6.8972.95 (3.25–12.11) 4.5271.75 (2.49–7.27)
Urine creatinine (Mmol/24 h) 4.972.14 (2.73–7.48) 5.1571.38 (3.59–7.17) 6.3871.98b (4.05–9.39) 5.7371.66 (3.34–7.2) 5.9871.72 (3.75–8.41) 5.1371.9 (1.72–7.25) 5.9572.08b (3.9–8.06)
Urine volume (l) 2.2270.98 (0.5–3.2) 2.0571.22 (0.5–4.05) 2.0270.95c (0.55–3.1) 1.9571.02 (0.45–3.6) 2.070.9 (0.8–3.7) 2.4471.24 (0.7–3.7) 1.8970.96 (0.65–3.52)
Plasma oxalate (mmol/l) 10.1775.52 (2.67–18.23) — — — — 6.7773.73c (0.64–11.76) —
Oxalate absorption (%) 8.971.99 (5.8–11.4) — — — — 6.472.77a (1.6–8.9) —
aPo0.02 vs baseline, bPo0.002 vs baseline and cPo0.05 vs baseline.
Table 2 | Mean values7s.d. (range) for urinary excretion parameters, urinary calcium-oxalate saturation, plasma oxalate, and intestinal oxalate absorption of the
patients with normal (No. 12 and No. 15–17) or stable (No. 13, No. 18 and No. 19) renal function included in the IxOC-3 study
Baseline Week 1 Week 2 Week 3 Week 4 Week 5 Week 6
Mean7s.d. (range) Mean7s.d. (range) Mean7s.d. (range) Mean7s.d. (range) Mean7s.d. (range) Mean7s.d. (range) Mean7s.d. (range)
Urinary oxalate (mmol/1.73m2/24 h) 1.8570.49 (0.74–2.49) 0.8370.44a (0.23–1.8) 1.0470.42a (0.34–1.5) 0.5370.18b (0.14–0.75) 0.7470.23b (0.23–0.94) 1.5970.71 (0.37–2.5) 0.8570.36a (0.48–1.64)
Calcium (mg/kg body weight/24 h) 0.9370.49 (0.42–1.89) 0.7170.4 (0.34–1.39) 1.0771.22 (0.12–3.42) 0.7270.47 (0.18–1.51) 1.2770.52 (0.59–2.07) 1.6471.1 (0.81–4.08) 1.3770.96 (0.66–3.42)
Citrate (mmol/1.73m2/24 h) 1.6770.9 (0.53–2.79) 1.4570.91 (0.35–2.89) 1.6670.94 (0.5–2.82) 1.470.77 (0.39–2.28) 1.7871.13 (0.54–3.34) 2.4571.71 (0.53–5.37) 1.870.78 (0.73–2.81)
Magnesium (mmol/1.73m2/24 h) 4.1672.08 (1.08–6.65) 4.2672.36 (2.39–7.94) 5.4971.5 (4.01–7.49) 5.6771.89 (3.67–8.43) 6.2172.25 (3.0–8.25) 5.0672.71 (2.74–10.08) 5.1671.92 (3.14–8.63)
bUCaOx (rel. units) 4.8372.45 (1.08–8.14) 2.9172.39 (1.16–2.39) 3.3173.1 (1.25–9.06) 2.6271.57
c (0.6–4.79) 3.0671.3c (1.58–5.43) 7.3573.43 (1.11–11.81) 2.8971.15 (1.16–4.01)
Urine creatinine (Mmol/24 h) 9.0673.93 (3.47–14.77) 6.6773.58a (3.26–10.65) 12.2673.23c (8.4–17.75) 9.4175.94 (8.83–21.7) 10.0774.88 (3.1–17.44) 8.6273.68 (2.47–13.75) 8.4374.06 (2.65–13.31)
Urine volume (l) 2.470.91 (1.55–4.2) 2.5570.55 (1.95–3.55) 2.5170.87 (1.8–4.05) 2.3970.84 (1.2–3.8) 2.5970.81 (1.8–4.1) 2.7170.89c (1.65–4.28) 2.5470.88 (1.9–4.2)
Plasma oxalate (mmol/l) 12.3274.98 (8.31–20.24) — — — — 8.0673.34c (1.69–11.34) —
Oxalate absorption (%) 6.4373.91 (1.6–11.4) — — — — 5.1372.59 (2–8.3) —
aPo 0.002 vs baseline, bPo 0.001 vs baseline and cPo0.05 vs baseline.
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IxOC-3 study (Table 2). The percentage of [13C2]oxalate
absorbed remained unchanged in two subjects, decreased in
nine subjects, and slightly increased in two subjects.
Overall, administration of O. formigenes was found to be a
safe treatment. Results of complete blood chemistry and
hematology performed at baseline and at week-5 showed no
significant changes in any of the parameters (data not
shown). We did not see any major side effect of oral
O. formigenes administration. Patients were only complaining
about the smell of the preparation (IxOC-2) and flatulence
was infrequently reported in both studies.
DISCUSSION
We were able to show that oral O. formigenes administration
is safe, that it transiently colonizes the intestinal tract, and
that it exerts its metabolic activity to enhance the non-
urinary removal of endogenous oxalate through enteric
elimination, thus supporting previous data in animal
models.22,23 The enteric elimination of oxalate has been
shown to be both through passive movements across a
transepithelial gradient or through specific colonic oxalate
secretory pathways.22 Enteric elimination is expected to be
predominant in PH patients, as their POx levels are at the
higher end of normal or even elevated. This is supported by
our observation of a significant reduction of POx in the
patients with normal or stable renal function in both studies
as well as in the two ESRF patients with good compliance in
the IxOC-2 study.
The IxOC-3 formulation, delivering O. formigenes safely
past the acidic conditions of the stomach, produced a 435%
decrease of urinary oxalate excretion (mmol/mol creatinine)
in 4/6 patients with normal renal function at treatment weeks
3 and 4. Reduction in the mean urinary oxalate excretion at
weeks 3 and 4 of treatment concomitantly produced a
significant decrease in the urinary CaOx-saturation index at
these weeks. The only available treatment for reduction of
urinary oxalate in PH 1 is the pyridoxine therapy and
considering the proposed mode of action of pyridoxine, this
treatment is not effective in patients with PH type 2.
Pyridoxine administration in daily doses of 5–20 mg/kg body
weight per day has been found to be effective at lowering the
urinary excretion of oxalate in approximately 30% of patients
(6). Also, a 30% or greater decrease of urinary oxalate upon
pyridoxine administration is considered a clinically relevant
value (1).
Every little decrease in UOx or POx produces a correspond-
ing decline in the CaOx saturation levels in urine or plasma,
thereby reducing the risk of recurrent urolithiasis, progressive
nephrocalcinosis, or systemic oxalosis. Reducing the UOx
levels in the approximate range of our short-term results
during long-term treatment would hence dramatically lessen
the risk of kidney damage and concomitant renal failure in
PH patients.
No kind of renal replacement therapy is capable of
eliminating sufficient amounts of oxalate.25,26 Hence, sys-
temic oxalosis develops, the course of the disease deteriorates,
Table 3 | Clinical and laboratory data of the patients who completed the IxOC-2 and IxOC-3 study
Subject
number Sex Age (years) Diagnosis S-Crea (mg/dl) AGXT mutation
AGT (lmol/h/mg
protein)
Renal
ultrasound Medication
1 F 14 PH 1 1.0 508G4A (hz) 5.02 Nephrocalcinosis B6, Alkali-citrate
2/16 M 10/11 PH 1 0.7 508G4A (hz) 5 Urolithiasis B6, Alkali-citrate
3/17 M 8/9 PH 1 0.6 508G4A (hz) ND* Urolithiasis B6, Alkali-citrate
4/15 F 5/6 PH 1 0.4 33delc (hoz) 1.7 Nephrocalcinosis B6, Alkali-citrate
6/14 F 21/22 PH 1 ESRF 508G4A (hoz) 9.4 Nephrocalcinosis B6
8 M 3.5 PH 1 ESRF 508G4A (hz) 5.3 Nephrocalcinosis B6
9 M 8 PH 1 0.53 n.m. 4.2 Urolithiasis B6, Alkali citrate
10/19 F 49/50 PH 1 1.6 508G4A (hz) 6.2 Urolithiasis B6, Alkali citrate
Nephrocalcinosis Steroids, CyA
Syst. oxalosis MMF
11 M 8 PH 1 ESRF ND ND Urolithiasis No PH medicines
12 M 15 PH 1 0.91 508G4A (hz) 5.5 Urolithiasis B6, Alkali-citrate
13 M 12.5 PH 1 1.6 508G4A (hoz) 9.0 Nephrocalcinosis B6, Alkali-citrate
18 M 15.5 PH 1 1.56 508G4A (hz) 5.3 Urolithiasis B6, Alkali citrate
AGT, alanine:glyoxylate aminotransferase (normal=19.1–47.9 mmol/h/mg protein); ESRF, end-stage renal failure; F, female; hz, heterozygote; hoz, homozygote; M, male; MMF,
mycophenolate mofetil; ND, not done; nd*, not done, as siblings value was informative; n.m., no mutation yet found; PH 1, primary hyperoxaluria type 1.
Patients no. 2–4, 6, and 10 participated in both studies.
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Figure 3 | Plasma oxalate levels in three patients with ESRF
treated with IxOC-2 for 4 or 5 weeks (no. 6), respectively. Right,
Y-axis depicts patient no. 8. Week 5 blood sample in patient no. 11
was only drawn 30 min after the start of dialysis and hence, plasma
oxalate was not determined.
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and later lessens the success of combined LKTx. Taken into
consideration, that even forced hemodialysis, for example,
five times per week, and additional peritoneal dialysis
does not sufficiently reduce POx over time, our results are
of utmost importance for the PH patients on dialysis.27
Although we did not achieve a decline of POx in all three
ESRF patients, two arguments still support the thesis that
oxalate is sufficiently eliminated via the intestinal tract in
ESRF: (1) we achieved a significant reduction in POx in the
two patients with good compliance (according to the diary,
O. formigenes was not administered every day in patient 11
since study week 2), and (2) clinical signs of systemic oxalosis
ameliorated in patients 6 (ESRF) and patient 10 (post
combined LKTx).
Although O. formigenes was detected in fecal samples in
the majority of patients during the treatment phase, it was
not correlated with the extent of treatment efficacy. The
culture and PCR-based detection of O. formigenes in the stool
samples is a qualitative test indicative of only the presence/
absence of the bacterium and therefore in this study
a correlation between the level of colonization and the
reduction in urinary oxalate excretion could not be
measured. Detection and quantification of bacteria in stool
samples has been reported to have low sensitivity and
specificity due to the nature of the sample matrix. Studies
with probiotic strains of Lactobacilli have shown that fecal
recovery of an orally fed strain starts with the consumption of
at least a 109 CFUs/day dose of encapsulated lactobacilli.28
Similarly, a double-blind, placebo-controlled study using
encapsulated L. fermentum ME-3 at a daily dose of log 9.2
CFUs showed that although the ME-3 strain did not reach
detectable levels in fecal samples, it exerted its metabolic
activity in the gut and produced a measurable biologic
effect.29 In the present study, although the fecal recovery of O.
formigenes was found to be higher with IxOC-2 treatment as
compared with IxOC-3, due to higher numbers of cell counts
fed, it is believed that the enteric-coated IxOC-3 capsules
delivered metabolically active live O. formigenes to the colonic
segment of the gastrointestinal-tract, which is the main site
for enteric elimination pathways.22 As observed with O.
formigenes treatment, many studies with bacterial supple-
mentation have shown that the ingested bacterial strains,
which survive the passage through the gut, transiently exert
their biological effect but neither persist nor become a part of
the normal gut microflora.29,30
The oxalate absorption test remained normalo10% or in
the wider normal range found for healthy adults of 2.2–18.5%
in all patients.24 This result appears reasonable since about
80% of the oxalate absorption takes place in the upper
intestine, normally not colonized by bacteria. The fact that
the excretion of orally supplied oxalate is unaffected clearly
demonstrates that it is the endogenous oxalate that is
removed by O. formigenes.
As treatment options in patients with PH are limited, new
therapeutic regimens are clearly needed. The data obtained in
this study let us speculate that O. formigenes might be a very
promising new kind of treatment for this mostly devastating
disease. It seems possible that endogenously produced
oxalate can be removed via the intestinal tract in addition
to being excreted via the kidneys. A decrease in UOx will
reduce bUCaOx and hence the risk of recurrent urolithiasis
or progressive nephrocalcinosis. According to the results
obtained in these two clinical studies, treatment with
O. formigenes may prove to be a viable treatment option
for PH patients with normal kidney function, with ESRF and
severe post-transplant oxalosis. However, further multicenter
studies with a larger patient population are clearly needed.
MATERIALS AND METHODS
Our study was divided into two parts according to the mode of
delivery of O. formigenes, to be given b.i.d. together with the main
meals for 4 weeks. In the first study, O. formigenes was administered
as a frozen cell paste containing 1 g live cells equivalent to 41010
CFUs (IxOC-2 study). In the second study, the patients took
two enteric-coated capsules per dosing (IxOC-3 study). Each
capsule contained 137 mg of lyophilized bulk powder of freeze-
dried live cells equivalent to B107 CFUs. The latter allowing a safe
delivery of the preparation past the stomach acid. Both prepara-
tions were provided by Ixion Biotechnology Inc., Alachua, FL,
USA. During both studies, the dosing compliance, adverse
events, and concomitant medication were monitored through the
patient’s diary.
PH 1 patients were eligible for the study and their clinical data is
shown in Table 3. Of the 11 patients included in the IxOC-2 study
(patients no. 1–11), nine completed the study, five with normal renal
function, one after combined LKTx and severe systemic oxalosis,
and three patients with ESRF and hemodialysis treatment. One
patient (no. 5) turned out to be not eligible, as she was finally
diagnosed with PH 2. The other patient (no. 7) was excluded after
the baseline examinations were performed, as the parents declined
their consent.
In the IxOC-3 study, eight patients were included (Table 3,
patient no. 12–19) and seven patients completed the study, six
patients with normal or stable renal function and one patient after
LKTx and stable graft function. Owing to noncompliance, patient 14
with ESRF was removed from the IxOC-3 study. This patient
eventually received an LKTx. Four patients had also completed the
treatment in the IxOC-2 study. Patient 15, a five-year-old girl, was
only able to swallow one capsule IxOC-3 per dosing.
Before treatment with O. formigenes, baseline evaluation
included 24 h urine analysis, a [13C2]oxalate absorption test,
a plasma oxalate (POx) determination, and stool analysis for
O. formigenes. Safety of the treatment was followed by performing
standard clinical laboratory tests (e.g., complete blood chemistry,
hematology, and urine analysis) before and after the treatment.
A b-HCG analysis was performed to exclude pregnant women
from the study.
During the administration of O. formigenes, the 24 h urine or
plasma samples (in the ESRF patients) were collected and analyzed
weekly. Oxalate absorption and POx were again analyzed at week 5 in
patients with normal renal function. During treatment, subjects
took their normal medication, ate their normal western, but low
oxalate diet, and patients with normal kidney function kept their
fluid intake 41.5 l per m2 body surface area. Weeks 5 and 6 of the
study served as short-term follow-up. Patients are since longi-
tudinally followed in our outpatients clinics.
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For urine collection, thymol ‘5% in isopropanol’ was added for
preservation. Total urine volume and pH was recorded and urinary
oxalate, sulfate, phosphate and citrate, urinary uric acid, sodium,
potassium, chloride, calcium, magnesium, specific gravity, and
creatinine were measured and bUCaOx was calculated according to
previous references.4,31 Urinary oxalate was expressed as mean 24 h
urinary excretion 7s.d. in mmol/1.73 m2/24 h, but as a molar
oxalate/creatinine ratio (mmol/mol) for individual patient data. POx
analysis was performed via ion chromatography.32
In the IxOC-2 study, detection of O. formigenes in stool samples
was performed using the PCR-based test.17 In the IxOC-3 study,
O. formigenes detection was performed by culture at the clinical site
as well as by PCR.17
For the oxalate absorption test, [13C2]-oxalate was used and the
absorption was measured by a gas chromatography-mass spectro-
metry method as previously published.24
A 420% reduction of urinary oxalate under treatment was
determined as successful end point in patients with normal renal
function and patients with such a reduction at both weeks 3 and 4 of
treatment were considered to be responders. For each follow-up
visit, the differences in the mean UOx for that visit and the mean
baseline UOx were tested for a difference from zero using the paired
t-test (SAS version 9.1 software, SAS, Cary, NC, USA) and Po0.05
were judged significant. The study was approved by the Ethical
Committees of the faculties of medicine of the Universities of Bonn
and Cologne, especially with regard to the use of the labeled oxalate.
Informed consent was obtained from the patients or their parents
for plasma and stool analysis, for the oxalate absorption test, and for
the application of either the IxOC-2 or IxOC-3 O. formigenes
preparation.
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